세계의 에피네프린 자가주사기 시장 보고서 : 용량별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global epinephrine autoinjector market size reached USD 2.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.3 Billion by 2033, exhibiting a growth rate (CAGR) of 7.8% during 2025-2033. The increasing number of individuals with allergies, rising need for self-administrating medicines, and the launch of smart epinephrine autoinjector represent some of the key factors driving the market.

Epinephrine autoinjector is a medical device used to administer single dose epinephrine easily for treating severe allergic reactions caused by stings, bug bites, or drugs. It is designed to deliver the medication into the thigh muscle of an individual and works by constricting blood vessels and dilating the airways to minimize the symptoms of an allergic reaction. It is small and easy to carry and can be administered by individuals or healthcare professionals. At present, leading manufacturers are introducing epinephrine autoinjector with multiple doses of medications and adjustable dosages that enable the user to adjust the dose according to the severity of the allergic reaction and improve the effectiveness of the treatment. They are also incorporating audio and visual instructions to make it easier for individuals to use them in an emergency.

Epinephrine Autoinjector Market Trends:

The increasing number of individuals with allergies and allergic reactions and the rising need for self-administrating medicines represent one of the major factors driving the demand for epinephrine autoinjectors around the world. Moreover, the surging prevalence of arthritis, asthma, cancer, and chronic obstructive pulmonary disease (COPD) and the growing aging population, which is more prone to develop allergic reactions, is influencing the market positively. In addition, the increasing incidence of food allergies among the masses is bolstering the growth of the market. Apart from this, governing agencies of numerous countries are undertaking initiatives to promote the use of epinephrine autoinjectors in schools and other public spaces. This, coupled with the rising awareness about epinephrine autoinjectors, is contributing to the market growth. Furthermore, key players are introducing smart epinephrine autoinjectors that are integrated with advanced technologies, including Bluetooth connectivity, sensors, and machine learning, to make them more convenient, user friendly, and effective. Leading players are also launching mobile applications that can be connected to smartphones or other devices, allowing remote monitoring, tracking of usage and expiration dates, and ensuring the patient does not exceed the recommended dosage. These advancements can also help predict the likelihood of an allergic reaction and provide personalized recommendations for treatment. This, along with the incorporation of an automated external defibrillator (AED) in epinephrine autoinjectors to offer a comprehensive emergency response system, is creating a positive outlook for the market.

Key Market Segmentation:

Dosage Insights:

• 0.15mg Epinephrine Autoinjector
• 0.3mg Epinephrine Autoinjector
• 0.5mg Epinephrine Autoinjector

Application Insights:

• Under 6 Years

6 to 12 Years

• Over 12 Years

End User Insights:

• Hospitals
• Clinics
• Others

Regional Insights:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for epinephrine autoinjectors. Some of the factors driving the North America epinephrine autoinjector market included the rising prevalence of allergies, increasing awareness about anaphylaxis, and the availability of cost-effective generic versions of autoinjectors.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global epinephrine autoinjector market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adamis Pharmaceuticals Corporation, Amneal Pharmaceuticals Inc., Antares Pharma Inc, Bausch Health, Kaleo Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global epinephrine autoinjector market performed so far, and how will it perform in the coming years ?
• What are the drivers, restraints, and opportunities in the global epinephrine autoinjector market ?
• What is the impact of each driver, restraint, and opportunity on the global epinephrine autoinjector market ?
• What are the key regional markets ?
• Which countries represent the most attractive epinephrine autoinjector markets ?
• What is the breakup of the market based on the dosage ?
• Which is the most attractive dosage in the epinephrine autoinjector market ?
• What is the breakup of the market based on the application ?
• Which is the most attractive application in the epinephrine autoinjector market ?
• What is the breakup of the market based on the end user ?
• Which is the most attractive end user in the epinephrine autoinjector market ?
• What is the competitive structure of the global epinephrine autoinjector market ?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Epinephrine Autoinjector Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Dosage

• 6.1 0.15mg Epinephrine Autoinjector
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 0.3mg Epinephrine Autoinjector
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 0.5mg Epinephrine Autoinjector
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Application

• 7.1 Under 6 Years
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 6 to 12 Years
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Over 12 Years
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Adamis Pharmaceuticals Corporation
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Amneal Pharmaceuticals Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
  • 14.3.3 Antares Pharma Inc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 SWOT Analysis
  • 14.3.4 Bausch Health
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Kaleo Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Teva Pharmaceutical Industries Ltd.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Viatris Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.